Carregant...
Randomized, Blinded Trial of Vitamin D(3) for Treating Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS)
PURPOSE: To evaluate the efficacy and safety of vitamin D(3) at 4,000 IU/day as a treatment option for aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) when compared with the usual care dose of 600 IU D(3). METHODS: Single site randomized, double-blind, phase 3 clinical trial in women...
Guardat en:
| Publicat a: | Breast Cancer Res Treat |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5260816/ https://ncbi.nlm.nih.gov/pubmed/26868123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3710-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|